Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study
Abstract Background Chronic inflammation has been described in people living with HIV (PLHIV) receiving antiretroviral therapy (ART) despite viral suppression. Inflammation associated non-communicable diseases, including atherosclerosis, are becoming recognized complication of HIV infection. We stud...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | AIDS Research and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12981-023-00506-2 |
| _version_ | 1797863477038022656 |
|---|---|
| author | Sirawat Srichatrapimuk Artit Wongsa Somnuek Sungkanuparph Sasisopin Kiertiburanakul Boonrat Tassaneetrithep Angsana Phuphuakrat |
| author_facet | Sirawat Srichatrapimuk Artit Wongsa Somnuek Sungkanuparph Sasisopin Kiertiburanakul Boonrat Tassaneetrithep Angsana Phuphuakrat |
| author_sort | Sirawat Srichatrapimuk |
| collection | DOAJ |
| description | Abstract Background Chronic inflammation has been described in people living with HIV (PLHIV) receiving antiretroviral therapy (ART) despite viral suppression. Inflammation associated non-communicable diseases, including atherosclerosis, are becoming recognized complication of HIV infection. We studied the effect of pitavastatin on atherosclerotic-associated inflammatory biomarkers in PLHIV receiving ART. Methods A randomized, double-blind, crossover study was conducted in HIV-infected persons with dyslipidemia and receiving atazanavir/ritonavir (ATV/r) to evaluate the effect of 2 mg/day pitavastatin treatment versus placebo. High-sensitivity CRP (hs-CRP), cytokines, and cellular markers in PLHIV receiving 12 weeks of pitavastatin or placebo were investigated. Results A total of 24 HIV-infected individuals with a median (interquartile range) age of 46 (41–54) years were recruited, and the median CD4 T cell count was 662 (559-827) cells/mm3. The median duration of ATV/r use was 36 (24–48) months. Significant change in levels of basic fibroblast growth factor (FGF) between pitavastatin treatment and placebo at week 12 from baseline was observed (27.1 vs. 20.5 pg/mL; p=0.023). However, there were no significant changes from baseline of hs-CRP and other plasma cytokine levels at week 12 of pitavastatin or placebo. Regarding cellular markers, percentages of HLA-DR+CD38-CD4+ T cells and PD1+CD4+ T cells significantly decreased from baseline in PLHIV receiving pitavastatin for 12 weeks, as compared to placebo (− 0.27 vs. 0.02%; p=0.049 and − 0.23 vs. 0.23%; p=0.022, respectively). Conclusions Pitavastatin treatment increases basic FGF levels, and lowers HLA-DR+CD38-CD4+ T cells, and PD1+CD4+ T cells. Further study on the effects of pitavastatin on preventing cardiovascular diseases in PLHIV should be pursued. |
| first_indexed | 2024-04-09T22:37:16Z |
| format | Article |
| id | doaj.art-8e51d3fdd1db45d7a9bbf4b8365035a8 |
| institution | Directory Open Access Journal |
| issn | 1742-6405 |
| language | English |
| last_indexed | 2024-04-09T22:37:16Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | AIDS Research and Therapy |
| spelling | doaj.art-8e51d3fdd1db45d7a9bbf4b8365035a82023-03-22T12:26:24ZengBMCAIDS Research and Therapy1742-64052023-02-012011810.1186/s12981-023-00506-2Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover studySirawat Srichatrapimuk0Artit Wongsa1Somnuek Sungkanuparph2Sasisopin Kiertiburanakul3Boonrat Tassaneetrithep4Angsana Phuphuakrat5Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol UniversityCenter of Research Excellence in Immunoregulation, Faculty of Medicine Siriraj Hospital, Mahidol UniversityChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol UniversityDivision of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol UniversityCenter of Research Excellence in Immunoregulation, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol UniversityAbstract Background Chronic inflammation has been described in people living with HIV (PLHIV) receiving antiretroviral therapy (ART) despite viral suppression. Inflammation associated non-communicable diseases, including atherosclerosis, are becoming recognized complication of HIV infection. We studied the effect of pitavastatin on atherosclerotic-associated inflammatory biomarkers in PLHIV receiving ART. Methods A randomized, double-blind, crossover study was conducted in HIV-infected persons with dyslipidemia and receiving atazanavir/ritonavir (ATV/r) to evaluate the effect of 2 mg/day pitavastatin treatment versus placebo. High-sensitivity CRP (hs-CRP), cytokines, and cellular markers in PLHIV receiving 12 weeks of pitavastatin or placebo were investigated. Results A total of 24 HIV-infected individuals with a median (interquartile range) age of 46 (41–54) years were recruited, and the median CD4 T cell count was 662 (559-827) cells/mm3. The median duration of ATV/r use was 36 (24–48) months. Significant change in levels of basic fibroblast growth factor (FGF) between pitavastatin treatment and placebo at week 12 from baseline was observed (27.1 vs. 20.5 pg/mL; p=0.023). However, there were no significant changes from baseline of hs-CRP and other plasma cytokine levels at week 12 of pitavastatin or placebo. Regarding cellular markers, percentages of HLA-DR+CD38-CD4+ T cells and PD1+CD4+ T cells significantly decreased from baseline in PLHIV receiving pitavastatin for 12 weeks, as compared to placebo (− 0.27 vs. 0.02%; p=0.049 and − 0.23 vs. 0.23%; p=0.022, respectively). Conclusions Pitavastatin treatment increases basic FGF levels, and lowers HLA-DR+CD38-CD4+ T cells, and PD1+CD4+ T cells. Further study on the effects of pitavastatin on preventing cardiovascular diseases in PLHIV should be pursued.https://doi.org/10.1186/s12981-023-00506-2AtherosclerosisDyslipidemiaHIV infectionInflammatory biomarkerPitavastatin |
| spellingShingle | Sirawat Srichatrapimuk Artit Wongsa Somnuek Sungkanuparph Sasisopin Kiertiburanakul Boonrat Tassaneetrithep Angsana Phuphuakrat Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study AIDS Research and Therapy Atherosclerosis Dyslipidemia HIV infection Inflammatory biomarker Pitavastatin |
| title | Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study |
| title_full | Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study |
| title_fullStr | Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study |
| title_full_unstemmed | Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study |
| title_short | Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study |
| title_sort | effects of pitavastatin on atherosclerotic associated inflammatory biomarkers in people living with hiv with dyslipidemia and receiving ritonavir boosted atazanavir a randomized double blind crossover study |
| topic | Atherosclerosis Dyslipidemia HIV infection Inflammatory biomarker Pitavastatin |
| url | https://doi.org/10.1186/s12981-023-00506-2 |
| work_keys_str_mv | AT sirawatsrichatrapimuk effectsofpitavastatinonatheroscleroticassociatedinflammatorybiomarkersinpeoplelivingwithhivwithdyslipidemiaandreceivingritonavirboostedatazanavirarandomizeddoubleblindcrossoverstudy AT artitwongsa effectsofpitavastatinonatheroscleroticassociatedinflammatorybiomarkersinpeoplelivingwithhivwithdyslipidemiaandreceivingritonavirboostedatazanavirarandomizeddoubleblindcrossoverstudy AT somnueksungkanuparph effectsofpitavastatinonatheroscleroticassociatedinflammatorybiomarkersinpeoplelivingwithhivwithdyslipidemiaandreceivingritonavirboostedatazanavirarandomizeddoubleblindcrossoverstudy AT sasisopinkiertiburanakul effectsofpitavastatinonatheroscleroticassociatedinflammatorybiomarkersinpeoplelivingwithhivwithdyslipidemiaandreceivingritonavirboostedatazanavirarandomizeddoubleblindcrossoverstudy AT boonrattassaneetrithep effectsofpitavastatinonatheroscleroticassociatedinflammatorybiomarkersinpeoplelivingwithhivwithdyslipidemiaandreceivingritonavirboostedatazanavirarandomizeddoubleblindcrossoverstudy AT angsanaphuphuakrat effectsofpitavastatinonatheroscleroticassociatedinflammatorybiomarkersinpeoplelivingwithhivwithdyslipidemiaandreceivingritonavirboostedatazanavirarandomizeddoubleblindcrossoverstudy |